Arcutis Announces Health Canada Approval of ZORYVE (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

GlobeNewswireOct 18 08:20 ET

Express News | Arcutis Announces Health Canada Approval of Zoryve® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

ReutersOct 18 08:20 ET

Arcutis Biotherapeutics, Inc (ARQT): A Small-Cap Leader in Skin Disease Treatments

Yahoo FinanceOct 12 10:18 ET

Possible Bearish Signals With Arcutis Biotherapeutics Insiders Disposing Stock

Simply Wall StOct 7 09:08 ET

Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Announces Target Price $19

Moomoo NewsOct 3 20:32 ET · Ratings

Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating

Moomoo NewsSep 27 14:31 ET · Ratings